Peripheral Neuropathy Under Anti-TNF Therapy in a Patient with Ulcerative Colitis: A Case Report

Infliximab is widely used in moderate to severe ulcerative colitis (UC). Neurological side effects of anti-TNF agents are uncommon, and when they occur it can be difficult to separate a drug reaction from a neurological manifestation of the disease itself. We report a 26-year-old woman with UC, revealed by steroid-refractory acute severe colitis, who received infliximab with azathioprine. After a 10-month interruption of treatment due to loss to follow-up, infliximab was restarted for a moderate flare. Eight days after the infusion, she presented with rapidly progressive symmetrical weakness of the four limbs, paresthesia and decreased reflexes. Electroneuromyography showed a mixed polyradiculoneuropathy, mainly in the lower limbs. Viral and syphilis serologies, vitamin B1, B9 and B12 levels, autoimmune tests and cerebrospinal fluid analysis were normal. Infliximab was stopped and the neurological signs disappeared spontaneously within six weeks. After discussion with the neurologists, infliximab was restarted, with no recurrence and good control of the colitis. In this patient, the clinical course suggests that the neuropathy was more likely an extra-intestinal manifestation of UC than a direct effect of infliximab.

Authors

Publication Details

Journal
Scholars Journal of Medical Case Reports
Published
2026-10-27
DOI
https://doi.org/10.36347/sjmcr.2026.v14i10.053
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Peripheral Neuropathy Under Anti-TNF Therapy in a Patient with Ulcerative Colitis: A Case Report

Mehdi Zouaoui, Youssef Hnach, Noureddine Aqodad, A. El Marzouqi et al.
Scholars Journal of Medical Case Reports
Peripheral Neuropathies and Disorders
article

Peripheral Neuropathy Under Anti-TNF Therapy in a Patient with Ulcerative Colitis: A Case Report

Mehdi Zouaoui, Youssef Hnach, Noureddine Aqodad, A. El Marzouqi, R. Faris, M. Azouaoui
article en

Abstract

Infliximab is widely used in moderate to severe ulcerative colitis (UC). Neurological side effects of anti-TNF agents are uncommon, and when they occur it can be difficult to separate a drug reaction from a neurological manifestation of the disease itself. We report a 26-year-old woman with UC, revealed by steroid-refractory acute severe colitis, who received infliximab with azathioprine. After a 10-month interruption of treatment due to loss to follow-up, infliximab was restarted for a moderate flare. Eight days after the infusion, she presented with rapidly progressive symmetrical weakness of the four limbs, paresthesia and decreased reflexes. Electroneuromyography showed a mixed polyradiculoneuropathy, mainly in the lower limbs. Viral and syphilis serologies, vitamin B1, B9 and B12 levels, autoimmune tests and cerebrospinal fluid analysis were normal. Infliximab was stopped and the neurological signs disappeared spontaneously within six weeks. After discussion with the neurologists, infliximab was restarted, with no recurrence and good control of the colitis. In this patient, the clinical course suggests that the neuropathy was more likely an extra-intestinal manifestation of UC than a direct effect of infliximab.

Scholars Journal of Medical Case ReportsVol. 14(10)
Openalex Percentile: Top 13%
Peripheral Neuropathies and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon